Halozyme Therapeutics (HALO) announced that argenx (ARGX) received European Commission approval of VYVGART 1000mg developed with ENHANZE, Halozyme’s proprietary recombinant human hyaluronidase enzyme, for subcutaneous injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy after prior treatment with corticosteroids or immunoglobulins. We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,” said Dr. Helen Torley, president and CEO of Halozyme. The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
- Merck granted review of Halozyme patent claims by PTAB
- Halozyme’s Strategic Positioning and Market Potential Drive Buy Rating
- Halozyme announces EC approval of Bristol Myers’ Opdivo developed with Enhanze
- Optimistic Buy Rating for Halozyme Amid Price Control Concerns